<DOC>
	<DOCNO>NCT02799784</DOCNO>
	<brief_summary>The primary objective study assess effect umeclidinium/vilanterol ( UMEC/VI ) versus tiotropium/olodaterol ( TIO/OLO ) subject moderate COPD . This multicentre , randomize , open label , 2 period crossover complete block design study . Eligible subject , complete 2-week run-in period , randomize receive sequence consist UMEC/VI inhalation powder ( 62.5/25 microgram [ mcg ] once-daily [ QD ] ) administer 1 inhalation via ELLIPTA® Inhaler TIO/OLO 5/5 mcg inhalation spray administer 2 inhalation via RESPIMAT® inhaler , 8 week . This follow 3-week washout period one-week follow-up period . The total duration subject participation study approximately 22 week . ELLIPTA register trademark GlaxoSmithKline group company . RESPIMAT register trademark Boehringer Ingelheim .</brief_summary>
	<brief_title>An Efficacy Study Umeclidinium/Vilanterol With Tiotropium/Olodaterol COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Outpatients either sex , 40 year age old Visit 1 , diagnosis chronic obstructive pulmonary disease ( COPD ) define American Thoracic Society/European Respiratory Society ( ERS ) A sign date write informed consent prior study participation A female eligible enter participate study pregnant ( confirm negative urine human chorionic gonadotrophin [ hCG ] test ) ; lactate ; nonreproductive potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal surgically sterile ) , define premenopausal female one following : document tubal ligation ; document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; hysterectomy ; document bilateral oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause ( refer laboratory reference range confirmatory level ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment OR A female reproductive potential , negative pregnancy test screening , agree one method GSK Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) requirement method use consistently correctly ( i.e. , accordance local approve product label per study investigator discretion instruction physician 30 day prior first dose study medication followup contact ) : GSK Modified List Highly Effective Methods Avoiding Pregnancy FRP ( list apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse long term persistent basis ) . Contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label Oral Contraceptive , either combined progestogen alone Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patch Male partner sterilization documentation azoospermia prior female subject 's entry study , male sole partner subject . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception Current former cigarette smoker history cigarette smoke &gt; =10 packyears . Former smoker define stop smoke least 6 month prior Visit 1 . Pipe and/or cigar use use calculate packyear history . A pre postalbuterol/salbutamol force expiratory volume one second ( FEV1 ) /Forced Vital Capacity ratio &lt; 0.70 postalbuterol/salbutamol FEV1 &lt; =70 % &gt; =50 % predict normal value Visit 1 . Predicted value base upon ERS ' Global Lung Function Initiative A score &gt; =2 Modified Medical Research Council Dyspnea Scale Visit 1 Women pregnant lactate plan become pregnant study A current diagnosis asthma Subjects alpha1 antitrypsin deficiency underlie cause COPD Subjects active tuberculosis exclude . Subjects respiratory disorder ( e.g . clinically significant : bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease ) exclude condition primary cause respiratory symptom . Any subject consider unlikely survive duration study period rapidly progress disease immediate lifethreatening illness ( e.g . cancer ) . In addition , subject condition ( e.g . neurological condition ) likely affect respiratory function include study Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator assessment Investigational Product use caution subject severe cardiovascular disease . In opinion investigator , use consider benefit likely outweigh risk condition : Myocardial infarction unstable angina last 6 month Unstable life threaten cardiac arrhythmia require intervention last 3 month New York Heart Association Class IV heart failure Any history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , sympathomimetic , lactose/milk protein magnesium stearate Subjects medical condition narrowangle glaucoma , urinary retention , prostatic hypertrophy , bladder neck obstruction exclude unless , opinion study physician , benefit outweighs risk Hospitalization COPD pneumonia within 12 week prior Visit 1 . Pneumonia and/or moderate severe COPD exacerbation resolve least 14 day prior Screening ( V1 ) least 30 day follow last dose oral/systemic corticosteroid ( applicable ) . Other respiratory tract infection resolve least 7 day prior Screening ( V1 ) . Subjects lung volume reduction surgery ( include procedure endobronchial valve ) within 12 month prior Screening ( V1 ) . The Investigator determine clinical significance abnormal electrocardiogram find relation subject 's medical history exclude subject would undue risk participate trial Unable withhold albuterol/salbutamol 4hour ( h ) period require prior spirometry test study visit Use predefined medication accord predefined defined time interval prior Screening ( Visit 1 ) Use longterm oxygen therapy describe rest oxygen therapy &gt; 3 liter ( L ) /minute ( min ) screening . ( Oxygen use &lt; =3 L/min flow exclusionary , patient may adjust oxygen level need study . ) Regular use ( prescribed daily/ regular use , asneeded use ) shortacting bronchodilator ( e.g . albuterol/salbutamol ) . Participation acute phase pulmonary rehabilitation program within 4 week prior Screening ( Visit 1 ) . Subjects maintenance phase pulmonary rehabilitation program exclude A known suspected history alcohol drug abuse within 2 year prior Screening ( Visit 1 ) opinion investigator would prevent subject complete study procedure Is investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member aforementioned involve study In opinion investigator , subject unable read and/or would able complete questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tiotropium</keyword>
	<keyword>COPD</keyword>
	<keyword>olodaterol</keyword>
	<keyword>Umeclidinium bromide</keyword>
	<keyword>efficacy</keyword>
	<keyword>vilanterol</keyword>
</DOC>